| Literature DB >> 27885886 |
Tait D Shanafelt1, Sameer A Parikh1, Peter A Noseworthy2, Valentin Goede3, Kari G Chaffee4, Jasmin Bahlo5, Timothy G Call6, Susan M Schwager6, Wei Ding6, Barbara Eichhorst7, Kirsten Fischer7, Jose F Leis8, Asher Alban Chanan-Khan9, Michael Hallek10, Susan L Slager11, Neil E Kay12.
Abstract
Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.Entities:
Keywords: Chronic lymphocytic leukemia; atrial fibrillation; ibrutinib; risk factors
Mesh：
Substances：
Year: 2016 PMID： 27885886 DOI： 10.1080/10428194.2016.1257795
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022